Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,219 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.
Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Krevvata M, Chen Y, Wang J, Kudva A, Ukropec J, Wroblewski S, Qi M, Kobos R, San-Miguel J. Mateos MV, et al. Among authors: yoon ss. Lancet. 2020 Jan 11;395(10218):132-141. doi: 10.1016/S0140-6736(19)32956-3. Epub 2019 Dec 10. Lancet. 2020. PMID: 31836199 Clinical Trial.
A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma.
Lee KW, Yun T, Song EK, Na II, Shin H, Bang SM, Lee JH, Lee ST, Kim JH, Yoon SS, Lee JS, Park S, Kim BK, Kim NK. Lee KW, et al. Among authors: yoon ss. J Korean Med Sci. 2005 Aug;20(4):598-62. doi: 10.3346/jkms.2005.20.4.598. J Korean Med Sci. 2005. PMID: 16100450 Free PMC article. Clinical Trial.
Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS, Kim K, Cheong JW, Min YH, Suh C, Kim H, Jo DY, Ryoo HM, Yoon SS, Lee JH; Korean Multiple Myeloma Working Party. Kim JS, et al. Among authors: yoon ss. Biol Blood Marrow Transplant. 2009 Apr;15(4):463-70. doi: 10.1016/j.bbmt.2008.12.512. Biol Blood Marrow Transplant. 2009. PMID: 19285634 Free article.
Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety.
Lee SS, Suh C, Kim BS, Chung J, Joo YD, Ryoo HM, Do YR, Jin JY, Kang HJ, Lee GW, Lee MH, Shim H, Kim K, Yoon SS, Bang SM, Kim HY, Lee JJ, Park J, Lee DS, Lee JH; Korean Multiple Myeloma Working Party. Lee SS, et al. Among authors: yoon ss. Ann Hematol. 2010 Sep;89(9):905-12. doi: 10.1007/s00277-010-0943-z. Epub 2010 Mar 27. Ann Hematol. 2010. PMID: 20349060 Clinical Trial.
Increased copy number of the interleukin-6 receptor gene is associated with adverse survival in multiple myeloma patients treated with autologous stem cell transplantation.
Kim SY, Min HJ, Park HK, Oh B, Kim TY, She CJ, Hwang SM, Kim M, Kim HK, Kim I, Yoon SS, Park S, Kim BK, Lee JH, Lee DS; Korea Multiple Myeloma Working Party. Kim SY, et al. Among authors: yoon ss. Biol Blood Marrow Transplant. 2011 Jun;17(6):810-20. doi: 10.1016/j.bbmt.2011.01.002. Epub 2011 Jan 8. Biol Blood Marrow Transplant. 2011. PMID: 21220034 Free article.
Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Kim HJ, Yoon SS, Lee DS, Sohn SK, Eom HS, Lee JL, Chung JS, Kim K, Suh C, Won JH, Kim JS, Park JS, Kang HJ, Seong CM, Kim CS, Lee SJ, Lee JH. Kim HJ, et al. Among authors: yoon ss. Ann Hematol. 2012 Feb;91(2):249-56. doi: 10.1007/s00277-011-1298-9. Epub 2011 Jul 26. Ann Hematol. 2012. PMID: 21789621 Clinical Trial.
Early response to bortezomib combined chemotherapy can help predict survival in patients with multiple myeloma who are ineligible for stem cell transplantation.
Lee HS, Kim YS, Kim K, Kim JS, Kim HJ, Min CK, Suh C, Eom HS, Yoon SS, Lee JH, Kim MK, Kim SH, Bae SH, Mun YC, Jo DY, Chung JS; Korean Multiple Myeloma Working Party (KMMWP). Lee HS, et al. Among authors: yoon ss. J Korean Med Sci. 2013 Jan;28(1):80-6. doi: 10.3346/jkms.2013.28.1.80. Epub 2013 Jan 8. J Korean Med Sci. 2013. PMID: 23341716 Free PMC article.
Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study.
Kim K, Lee JH, Kim JS, Min CK, Yoon SS, Shimizu K, Chou T, Kosugi H, Suzuki K, Chen W, Hou J, Lu J, Huang XJ, Huang SY, Chng WJ, Tan D, Teoh G, Chim CS, Nawarawong W, Siritanaratkul N, Durie BG. Kim K, et al. Among authors: yoon ss. Am J Hematol. 2014 Jul;89(7):751-6. doi: 10.1002/ajh.23731. Epub 2014 Apr 26. Am J Hematol. 2014. PMID: 24723430 Free article.
1,219 results